BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Clinical Outcome
6 results:

  • 1. High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis.
    De Luca G; Lev PR; Camacho MF; Goette NP; Sackmann F; Castro Ríos MA; Moiraghi B; Cortes Guerrieri V; Bendek G; Carricondo E; Enrico A; Vallejo V; Varela A; Khoury M; Gutierrez M; Larripa IB; Marta RF; Glembotsky AC; Heller PG
    Front Immunol; 2023; 14():1161832. PubMed ID: 38035089
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis.
    Longhitano L; Tibullo D; Vicario N; Giallongo C; La Spina E; Romano A; Lombardo S; Moretti M; Masia F; Coda ARD; Venuto S; Fontana P; Parenti R; Li Volti G; Di Rosa M; Palumbo GA; Liso A
    Aging (Albany NY); 2021 Dec; 13(23):25055-25071. PubMed ID: 34905501
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A; Barbui T
    Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Genetic-pathologic characterization of myeloproliferative neoplasms.
    Kim Y; Park J; Jo I; Lee GD; Kim J; Kwon A; Choi H; Jang W; Chae H; Han K; Eom KS; Cho BS; Lee SE; Yang J; Shin SH; Kim H; Ko YH; Park H; Jin JY; Lee S; Jekarl DW; Yahng SA; Kim M
    Exp Mol Med; 2016 Jul; 48(7):e247. PubMed ID: 27444979
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Expression of p-jak2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia.
    Ikezoe T; Kojima S; Furihata M; Yang J; Nishioka C; Takeuchi A; Isaka M; Koeffler HP; Yokoyama A
    Int J Cancer; 2011 Nov; 129(10):2512-21. PubMed ID: 21207414
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
    Tefferi A
    Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.